Literature DB >> 15560811

Healing, post-operative morbidity and patient perception of outcomes following regenerative therapy of deep intrabony defects.

Maurizio S Tonetti1, Ioannis Fourmousis, Jeanie Suvan, Pierpaolo Cortellini, Urs Brägger, Niklaus P Lang.   

Abstract

AIM: This prospective multicenter randomized controlled clinical trial was designed to compare the clinical outcomes of papilla preservation flap surgery with or without the application of enamel matrix derivatives (EMD). This article reports on early healing events, post-operative morbidity and patient perceptions of the surgical outcomes.
MATERIAL AND METHODS: One hundred and seventy-two patients with advanced chronic periodontitis and at least one intrabony defect of > or =3 mm were recruited in 12 centres in seven countries (European Research Group on Periodontology (ERGOPERIO)). Papilla preservation flaps were used to obtain access and primary closure. After debridement, and root conditioning, EMD was applied in the test subjects, and omitted in the controls. Healing was monitored 1, 2, 3, 4, 6 and 12 weeks after surgery. During the first 12 weeks of healing, supracrestal soft-tissue density was evaluated with a computer-assisted densitometric image analysis system (CADIA) using underexposed radiographs taken on a subset of 34 patients. Patient perceptions were evaluated with a questionnaire immediately after the procedure, at suture removal 1 week later and at 1 year.
RESULTS: Subjects reported little intraoperative or post-operative pain or discomfort for both test and controls. Twenty-four percent of controls and 30% of tests (p=0.64) reported a degree of interference with daily activities for an average of 3 and 3.5 days, respectively. Post-surgical edema was noted in 25% of tests and 28% of controls. Wound dehiscence in the interdental portion of the flap was uncommon (14% of tests and 12% of controls at week 1) and of limited size. Root sensitivity was the most frequent post-operative adverse event: it affected 45% of test and 35% of controls (p=0.55). Up to 6 weeks post-operatively, soft-tissue densities were significantly higher in subjects treated with EMD with respect to controls. One year after completion of the surgery, patients reported high levels of satisfaction with the outcomes. The most frequently reported benefits included the ability to preserve a tooth/dentition and to maintain/improve chewing ability. The cost and need for frequent follow-ups were cited as significant drawbacks.
CONCLUSIONS: This study portrayed the early healing events, pain, discomfort and adverse events of papilla preservation flap surgery and the 1-year patient perceptions of the benefits and disadvantages of periodontal surgery in intrabony defects. Earlier gains in soft-tissue density were observed following application of EMD. In terms of patient-centered outcomes, however, both procedures performed in a similar manner.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15560811     DOI: 10.1111/j.1600-051X.2004.00615.x

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  21 in total

Review 1.  Enamel matrix derivative and bone grafts for periodontal regeneration of intrabony defects. A systematic review and meta-analysis.

Authors:  M Matarasso; V Iorio-Siciliano; A Blasi; L Ramaglia; G E Salvi; A Sculean
Journal:  Clin Oral Investig       Date:  2015-05-27       Impact factor: 3.573

2.  Three-year results following regenerative periodontal surgery of advanced intrabony defects with enamel matrix derivative alone or combined with a synthetic bone graft.

Authors:  Thomas Hoffmann; Elyan Al-Machot; Jörg Meyle; Pia-Merete Jervøe-Storm; Søren Jepsen
Journal:  Clin Oral Investig       Date:  2015-07-15       Impact factor: 3.573

3.  Effect of enamel matrix derivative on wound healing following gingival recession coverage using the modified coronally advanced tunnel and subepithelial connective tissue graft: a randomised, controlled, clinical study.

Authors:  Alexandra Stähli; Jean-Claude Imber; Elena Raptis; Giovanni E Salvi; Sigrun Eick; Anton Sculean
Journal:  Clin Oral Investig       Date:  2019-07-09       Impact factor: 3.573

4.  Anti-inflammatory effects of EMD in the presence of biomechanical loading and interleukin-1β in vitro.

Authors:  Marjan Nokhbehsaim; Birgit Deschner; Jochen Winter; Christoph Bourauel; Andreas Jäger; Søren Jepsen; James Deschner
Journal:  Clin Oral Investig       Date:  2011-01-12       Impact factor: 3.573

5.  Assessment of early discomfort and wound healing outcomes after periodontal surgery with and without enamel matrix derivative: an observational retrospective case-control study.

Authors:  Jae-Hong Lee; Ye-Sol Park; Yeon-Tae Kim; Do-Hyung Kim; Seong-Nyum Jeong
Journal:  Clin Oral Investig       Date:  2019-05-12       Impact factor: 3.573

Review 6.  Enamel matrix derivative (Emdogain(R)) for periodontal tissue regeneration in intrabony defects.

Authors:  Marco Esposito; Maria Gabriella Grusovin; Nikolaos Papanikolaou; Paul Coulthard; Helen V Worthington
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

7.  Enamel matrix derivative improves gingival fibroblast cell behavior cultured on titanium surfaces.

Authors:  Yulan Wang; Yufeng Zhang; Dai Jing; Yang Shuang; Richard J Miron
Journal:  Clin Oral Investig       Date:  2015-08-14       Impact factor: 3.573

8.  A novel flapless approach versus minimally invasive surgery in periodontal regeneration with enamel matrix derivative proteins: a 24-month randomized controlled clinical trial.

Authors:  Mario Aimetti; Francesco Ferrarotti; Giulia Maria Mariani; Federica Romano
Journal:  Clin Oral Investig       Date:  2016-04-05       Impact factor: 3.573

9.  The Prevalence of Root Sensitivity following Periodontal Therapy: A Systematic Review.

Authors:  Y H Lin; D G Gillam
Journal:  Int J Dent       Date:  2012-10-31

10.  Enamel matrix protein derivatives: role in periodontal regeneration.

Authors:  Vandana J Rathva
Journal:  Clin Cosmet Investig Dent       Date:  2011-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.